Since the introduction of several new innovative treatment options for metastatic castration resistant prostate cancer (mCRPC) it has become evident that no single therapy will meet the needs of all patients. The disease is heterogeneous in nature with coexistence of tumour cell clones with functional androgen receptors as well as clones with dysfunctional or absent androgen receptors within an individual patient. Consequently, clinical outcomes are often unpredictable. Many patients respond very well to androgen receptor targeted treatment whereas a significant fraction of patients seems to be primary resistant to such treatment approach1,2. Ongoing prospective, biomarker driven trials in mCRPC patients aim to shed light on the underlying molecular mechanisms behind the clinical responses to various treatent modalities. Ultimately, these studies will provide evidence to guide future treatment choices.
We wish to establish a forum for discussion of the ongoing research and currently available evidence in this field by providing an opportunity for you to interact with international and national experts and peers from the Nordic and Baltic region in hopes of achieving optimal patient outcomes.
A number of experts from US, Europe and the Nordic region will present, discuss and share best practice at the 2nd Nordic & Baltic Symposium for urologists and oncologists.
Please mark your calendar for September 17th 2015.
The symposium will take place in the afternoon in Arlanda, Stockholm. The symposium will be chaired by Urology Professor Michael Borre, Denmark and Oncology Professor Anders Widmark, Sweden. Professor Emmanuel Antonarakis from John Hopkins, US and Professor Nicolas Mottet, University Jean Monnet, France will each give keynote lectures on clinical implications of androgen receptor variants and treatment selection for individual mCRPC patients, respectively. We will soon be able to send you the final agenda with all the speakers. In the last part of the symposium we have organised “Meet the Professor Workshops” where you in smaller groups will get an opportunity to discuss patient cases and best practice with the invited professors and your peers.
You can already now secure your participation by replying back to your local Sanofi contact.
We are looking forward spending an interesting afternoon with you.